Sui-Yi Xu

Dr. Sui-Yi Xu

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Clinical Interventions in Aging
Verified
Journal Article
Open access
PDF file
SHSi-Jia Hou
Si-Jia Hou
SZSheng-Xiao Zhang
Sheng-Xiao Zhang
YLYang Li
Yang Li
SXSui-Yi Xu
Sui-Yi Xu
Alzheimer’s disease (AD) is a sporadic or familial neurodegenerative disease of insidious onset with progressive cognitive decline. Although numerous studies have been conducted or are underway on AD, there are still no effective drugs to reverse the pathological features and clinical manifestations of AD. Rapamycin is a macrolide antibiotic produced by Streptomyces hygroscopicus. As a classical mechanistic target of rapamycin (mTOR) inhibitor, rapamycin has been shown to be beneficial in a variety of AD mouse and cells models, both before the onset of disease symptoms and the early stage of disease. Although many basic studies have demonstrated the therapeutic effects of rapamycin in AD, many questions and controversies remain. This may be due to the variability of experimental models, different modes of administration, dose, timing, frequency, and the availability of drug-targeting vehicles. Rapamycin may delay the development of AD by reducing β-amyloid (Aβ) deposition, inhibiting tau protein hyperphosphorylation, maintaining brain function in APOE ϵ4 gene carriers, clearing chronic inflammation, and improving cognitive dysfunction. It is thus expected to be one of the candidates for the treatment of Alzheimer’s disease.

14 May 2024 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
MYMeng-Fan Yang
Meng-Fan Yang
DRDong-Xue Ren
Dong-Xue Ren
XPXue Pan
Xue Pan
CLChang-Xin Li
Chang-Xin Li
SXSui-Yi Xu
Sui-Yi Xu
Cortical spreading depression (CSD) is a slow wave of cortical depolarization closely associated with migraines with an aura. Previously, it was thought that CSD depolarization was mainly driven by neurons, with characteristic changes in neuronal swelling and increased extracellular potassium (K+) and glutamate. However, the role of astrocytes, a member of the neurovascular unit, in migraine with CSD has recently received increasing attention. In the early stages of CSD, astrocytes provide neurons with energy support and clear K+ and glutamate from synaptic gaps. However, in the late stages of CSD, astrocytes release large amounts of lactic acid to exacerbate hypoxia when the energy demand exceeds the astrocytes’ compensatory capacity. Astrocyte endfoot swelling is a characteristic of CSD, and neurons are not similarly altered. It is primarily due to K+ influx and abnormally active calcium (Ca2+) signaling. Aquaporin 4 (AQP-4) only mediates K+ influx and has little role as an aquaporin. Astrocytes endfoot swelling causes perivascular space closure, slowing the glymphatic system flow and exacerbating neuroinflammation, leading to persistent CSD. Astrocytes are double-edged swords in migraine with CSD and may be potential targets for CSD interventions.

7 December 2021 in Medical Science Monitor
Verified
Journal Article
Open access
SXSui-Yi Xu
Sui-Yi Xu
MSMao-Mei Song
Mao-Mei Song
LLLing Li
Ling Li
CLChang-xin Li
Chang-xin Li
Adie’s Pupil: A Diagnostic Challenge for the Physician - Article abstract #934657

2 April 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
WSWen-Xiu Sun
Wen-Xiu Sun
TCTing-Yan Chen
Ting-Yan Chen
MSMao-Mei Song
Mao-Mei Song
YGYing-Jie Gao
Ying-Jie Gao
SXSui-Yi Xu
Sui-Yi Xu
Many migraine triggers, such as stress, sleep deprivation, fatigue, strenuous exercise, and fasting, are potentially linked to disturbances in brain energy metabolism, mitochondrial function, and oxidative stress. Alongside efforts to avoid modifiable factors, prophylactic migraine treatments that target brain energy metabolism have garnered increasing attention. However, the current evidence supporting the use of energy-modulating drugs in migraine treatment guidelines remains weak. This narrative review explores the relationship between energy metabolism and cortical spreading depression susceptibility, metabolic alterations in migraine (including glucose and insulin metabolism, insulin resistance, lipid metabolism, and energy metabolism imaging markers), oxidative stress and antioxidant defenses, mitochondrial dysfunction, and the role of energy metabolism-targeted medications in migraine management. Nutrients may help improve mitochondrial function, thereby alleviating brain energy metabolism deficits and oxidative stress in migraine.

1 January 2015 in Neural Regeneration Research
Verified
Journal Article
Open access
PDF file
WLWei-Ping Li
Wei-Ping Li
SXSui-Yi Xu
Sui-Yi Xu
FHFeng-Yun Hu
Feng-Yun Hu
LRLi-Jie Ren
Li-Jie Ren
LCLei Chen
Lei Chen
XZXie-Jun Zhang
Xie-Jun Zhang
Therapeutic hypothermia is the most promising non-pharmacological neuroprotective strategy against ischemic injury. However, shivering is the most common adverse reaction. Many studies have shown that dantrolene is neuroprotective in in vitro and in vivo ischemic injury models. In addition to its neuroprotective effect, dantrolene neutralizes the adverse reaction of hypothermia. Dantrolene may be an effective adjunctive therapy to enhance the neuroprotection of hypothermia in treating ischemic stroke. Cortical neurons isolated from rat fetuses were exposed to 90 minutes of oxygen-glucose deprivation followed by reoxygenation. Neurons were treated with 40 μM dantrolene, hypothermia (at 33°C), or the combination of both for 12 hours. Results revealed that the combination of dantrolene and hypothermia increased neuronal survival and the mitochondrial membrane potential, and reduced intracellular active oxygen cytoplasmic histone-associated DNA fragmentation, and apoptosis. Furthermore, improvements in cell morphology were observed. The combined treatment enhanced these responses compared with either treatment alone. These findings indicate that dantrolene may be used as an effective adjunctive therapy to enhance the neuroprotective effects of hypothermia in ischemic stroke.

17 November 2025 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
MSMao‐Mei Song
Mao‐Mei Song
TCTing‐Yan Chen
Ting‐Yan Chen
SSShi‐Na Song
Shi‐Na Song
YGYing‐Jie Gao
Ying‐Jie Gao
CLChang-xin Li
Chang-xin Li
SXSui-Yi Xu
Sui-Yi Xu
Aims: C‐X‐C motif chemokine ligand 10 (CXCL10) is a member of the CXC chemokine family, known as a classical pain‐related chemokine. While CXCL10 is implicated in neuropathic pain, its role in vestibular migraine (VM) remains unclear. Methods: Serum CXCL10 levels correlated with dizziness and headache severity in VM patients. In the rat VM model, CXCL10, C‐X‐C motif chemokine receptor 3 (CXCR3), and phosphatidylinositol 4,5‐bisphosphate 3‐kinase (PI3K)/protein kinase B (AKT) signaling pathway expression were evaluated to explore the potential mechanisms of CXCL10 in VM. Results: Serum CXCL10 levels in VM patients were significantly elevated and positively correlated with headache and dizziness severity. In the rat VM model, CXCL10 and CXCR3 expression in the trigeminal nucleus caudalis and vestibular nuclei were significantly increased. Additionally, molecules related to the PI3K/AKT signaling pathway and downstream inflammatory factors showed significantly elevated expression. Conclusion: CXCL10 activates the PI3K/AKT signaling pathway, promoting the release of inflammatory factors, including interleukin‐1β, interleukin‐6, and tumor necrosis factor‐α, and is thus involved in the pathogenesis of VM.